184 related articles for article (PubMed ID: 37895147)
41. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
Haroun F; Millado K; Tabbara I
Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
[TBL] [Abstract][Full Text] [Related]
42. Erdheim-Chester Disease: a Concise Review.
Papo M; Emile JF; Maciel TT; Bay P; Baber A; Hermine O; Amoura Z; Haroche J
Curr Rheumatol Rep; 2019 Dec; 21(12):66. PubMed ID: 31807955
[TBL] [Abstract][Full Text] [Related]
43. Effective High-dose Interferon-α Therapy in a 13-Year-Old Girl With Erdheim-Chester Disease.
Tezol O; Citak EC; Ayhan YS; Balci Y; Koc ZP; Yuyucu Karabulut Y
J Pediatr Hematol Oncol; 2020 May; 42(4):326-331. PubMed ID: 31259822
[TBL] [Abstract][Full Text] [Related]
44. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
[TBL] [Abstract][Full Text] [Related]
45. Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.
Garg N; Lavi ES
J Neuroimaging; 2021 Jan; 31(1):35-44. PubMed ID: 32920940
[TBL] [Abstract][Full Text] [Related]
46. Erdheim-Chester disease involving the breast--a rare but important differential diagnosis.
Guo S; Yan Q; Rohr J; Wang Y; Fan L; Wang Z
Hum Pathol; 2015 Jan; 46(1):159-64. PubMed ID: 25454479
[TBL] [Abstract][Full Text] [Related]
47. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
48. [Erdheim-Chester disease: a rare histiocytosis with outstanding response to cobimetinib.].
Sosa GA; Dogliani P; Guidi AE; Marangoni MA; Lavarda M; Fainstein-Day P
Rev Fac Cien Med Univ Nac Cordoba; 2021 Dec; 78(4):398-401. PubMed ID: 34962740
[TBL] [Abstract][Full Text] [Related]
49. A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.
Bunaux K; Sevestre H; Emile JF; Capel C; Chenin L; Peltier J
Neurochirurgie; 2018 Dec; 64(6):439-441. PubMed ID: 30274919
[TBL] [Abstract][Full Text] [Related]
50. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
[TBL] [Abstract][Full Text] [Related]
51. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
[TBL] [Abstract][Full Text] [Related]
52. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
53. Association between Ischemic Stroke and Erdheim-Chester Disease: A Case Report and Review of Literature.
Fargeot G; Stefanizzi S; Depuydt S; Klapczynski F; Ameri A
J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e153-e155. PubMed ID: 28623120
[TBL] [Abstract][Full Text] [Related]
54. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
55. Vemurafenib as first-line therapy in
Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352
[TBL] [Abstract][Full Text] [Related]
56. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
57. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
58. Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases.
Alcedo PE; Gutierrez-Rodrigues F; Patel BA
Semin Hematol; 2022 Jul; 59(3):156-166. PubMed ID: 36115693
[TBL] [Abstract][Full Text] [Related]
59. Erdheim-Chester disease: a systematic review.
Cives M; Simone V; Rizzo FM; Dicuonzo F; Cristallo Lacalamita M; Ingravallo G; Silvestris F; Dammacco F
Crit Rev Oncol Hematol; 2015 Jul; 95(1):1-11. PubMed ID: 25744785
[TBL] [Abstract][Full Text] [Related]
60. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.
Cangi MG; Biavasco R; Cavalli G; Grassini G; Dal-Cin E; Campochiaro C; Guglielmi B; Berti A; Lampasona V; von Deimling A; Sabbadini MG; Ferrarini M; Doglioni C; Dagna L
Ann Rheum Dis; 2015 Aug; 74(8):1596-602. PubMed ID: 24671772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
